{"id":242994,"date":"2012-03-26T04:06:02","date_gmt":"2012-03-26T04:06:02","guid":{"rendered":"http:\/\/www.eugenesis.com\/using-viruses-to-beat-superbugs\/"},"modified":"2012-03-26T04:06:02","modified_gmt":"2012-03-26T04:06:02","slug":"using-viruses-to-beat-superbugs","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/using-viruses-to-beat-superbugs.php","title":{"rendered":"Using viruses to beat superbugs"},"content":{"rendered":"<p><p>Public  release date: 25-Mar-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Laura Udakis    <a href=\"mailto:l.udakis@sgm.ac.uk\">l.udakis@sgm.ac.uk<\/a>    44-118-988-1843    Society    for General Microbiology<\/p>\n<p>    Viruses that can target and destroy bacteria have the potential    to be an effective strategy for tackling hard-to-treat    bacterial infections. The development of such novel therapies    is being accelerated in response to growing antibiotic    resistance, says Dr David Harper at the Society for General    Microbiology's Spring Conference in Dublin.  <\/p>\n<p>    Bacteriophages are viruses that can infect bacteria and    multiply within them, breaking down the cell and destroying the    bacteria - amplifying themselves in the process to deal with    more bacteria. They are found everywhere including in river    water, soil, sewage and on the human body. Soon after their    initial discovery in 1915, bacteriophages were investigated as    antibacterial therapeutic agents. A limited understanding of    their mode of action meant early work was often unsuccessful    and with the advent of the chemical antibiotic era,    bacteriophages were passed over as therapeutics.  <\/p>\n<p>    Dr Harper, Chief Scientific Officer at AmpliPhi Bioscience in    Bedfordshire explains why bacteriophages are being revisited as    antibacterial agents. \"Each bacteriophage is highly specific to    a certain type of bacteria and needs the right bacterial host    cell in order to multiply. The more bacterial targets there    are, the quicker they grow by killing the host cells. Therefore    it seems very likely that infections harbouring high numbers of    bacteria will benefit most from bacteriophage therapy  for    example chronically infected ears, lungs and wounds,\" he said.    \"For these types of infection, only a tiny dose of the virus is    needed - as small as one thousandth of a millionth of a gram.    This can usually be administered directly to the site of    infection in a spray, drops or a cream. The major advantage to    bacteriophages is that they don't infect human cells so seem    likely to be very safe to use.\"  <\/p>\n<p>    Increasing resistance to antibiotics has meant that bacterial    infections are becoming more and more difficult to treat. With    fewer antibiotics available to treat drug-resistant infections,    research into bacteriophage therapy has been accelerated. \"The    rate of new antibiotics coming onto the market does not match    the rate of increasing drug-resistance. The need for new    approaches to counter such high resistance is both urgent and    vital. New approaches will save lives,\" stressed Dr Harper.  <\/p>\n<p>    Clinical trials for bacteriophage therapy are now underway. The    first clinical trial for safety was reported in 2005 and the    results demonstrating the effectiveness of bacteriophage    therapy were published in 2009. This clinical trial was    conducted by AmpliPhi. The company is planning further clinical    trials in conditions where existing antibacterial therapies are    not able to help. \"With the results of further clinical trials,    once regulatory issues are overcome and future investment    secured in this area of research, this should lead to the    development of novel products suitable for widespread use to    tackle bacterial diseases and overcome antibiotic resistance\",    said Dr Harper.  <\/p>\n<p>    ###  <\/p>\n<\/p>\n<p>        AAAS and EurekAlert! are not responsible for the accuracy    of news releases posted to EurekAlert! by contributing    institutions or for the use of any information through the    EurekAlert! system.  <\/p>\n<\/p>\n<p>See the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-03\/sfgm-uvt032212.php\" title=\"Using viruses to beat superbugs\">Using viruses to beat superbugs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 25-Mar-2012 [ | E-mail | Share ] Contact: Laura Udakis <a href=\"mailto:l.udakis@sgm.ac.uk\">l.udakis@sgm.ac.uk<\/a> 44-118-988-1843 Society for General Microbiology Viruses that can target and destroy bacteria have the potential to be an effective strategy for tackling hard-to-treat bacterial infections. The development of such novel therapies is being accelerated in response to growing antibiotic resistance, says Dr David Harper at the Society for General Microbiology's Spring Conference in Dublin. Bacteriophages are viruses that can infect bacteria and multiply within them, breaking down the cell and destroying the bacteria - amplifying themselves in the process to deal with more bacteria <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/microbiology\/using-viruses-to-beat-superbugs.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577473],"tags":[],"class_list":["post-242994","post","type-post","status-publish","format-standard","hentry","category-microbiology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242994"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=242994"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=242994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=242994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=242994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}